Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERACYTE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERACYTE's regulatory disclosures and financial reporting.
VCYT files a notice of a proposed affiliate sale of 6,658 Restricted Stock Units. The filing lists the securities to be sold as Common — Restricted Stock Units with an effective date of 03/02/2026. The excerpt also shows a prior 10b5-1 sale of 10,739 common shares on 12/16/2025 attributed to Ann McGuire and identifies Morgan Stanley Smith Barney LLC as the broker.
Marc Stapley reported a sale of 15,000 common shares on 01/22/2026, with proceeds shown as $1,915,576.23. The filing also lists intended issuer-side units: 34,398 Performance Stock Units dated 02/26/202611,125 Restricted Stock Units dated 03/02/2026
The transactions are reported on a Form 144 and the sale was routed through Morgan Stanley Smith Barney LLC on the NASDAQ market.
Veracyte, Inc. senior vice president and general counsel Annie McGuire reported a tax-related share disposition tied to restricted stock units. On March 2, 2026, 6,902 shares of common stock at $36.01 per share were withheld to cover tax obligations in connection with RSU vesting and did not represent a sale. After this withholding, she directly owned 101,364 shares of Veracyte common stock.
VERACYTE, INC. executive Jonathan Wygant, the VP and Chief Accounting Officer, reported a tax-related share disposition. On March 2, 2026, 3,006 shares of common stock were withheld at $36.01 per share to cover tax obligations from vesting restricted stock units, and the footnote states this does not represent a sale. Following this withholding, he directly holds 34,909 shares of Veracyte common stock, including 495 shares purchased on January 31, 2026 through the company’s Employee Stock Purchase Plan.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported a Form 4 transaction involving company common stock. On March 2, 2026, 7,234 shares were withheld at a price of $36.01 per share to cover tax obligations tied to vesting restricted stock units and, as the disclosure notes, this does not represent a sale. After this tax-withholding disposition, Chambers directly owns 149,537 shares of Veracyte common stock.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported an automatic share disposition related to tax withholding. On March 2, 2026, 7,517 shares of common stock were withheld at a price of $36.01 per share to cover taxes on vesting restricted stock units, leaving him with 112,840 directly owned shares. The filing specifies this did not represent an open-market sale.
Veracyte, Inc. executive Phillip G. Febbo reported two stock transactions on March 2, 2026. The company withheld 6,035 shares of common stock at $36.01 per share to cover his tax obligations from vesting restricted stock units, which is not a market sale. He also completed an open-market sale of 13,425 shares at a weighted average price of $36.1586 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 117,346 shares of Veracyte common stock.
VERACYTE, INC. Chief Executive Officer Marc Stapley reported a tax-related share disposition. On March 2, 2026, 19,455 shares of common stock were withheld to satisfy tax obligations tied to vesting restricted stock units at a reference price of $36.01 per share. Following this withholding, he directly owns 403,077 shares of Veracyte common stock. The footnote clarifies this was not an open-market sale but a tax-withholding transaction.